{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:07:47Z","timestamp":1789106867813,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Capecitabine stands as a pivotal chemotherapeutic agent in gastric cancer (GC) management. While its general safety profile has been documented, comparative pharmacovigilance analyses of distinct capecitabine-based treatment regimens among GC patients remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study extracted AE reports from the United States Food and Drug Administration AE Reporting System (FAERS) for the period 2004 Q1-2024 Q4. Following rigorous data cleansing, the adverse event (AE) reports were systematically standardized using the system organ class (SOC) and preferred term (PT) terminology from the Medical Dictionary for Regulatory Activities (MedDRA, version 26.0). Four disproportionality algorithms were employed to detect and analyze AE signals across four cohorts. Cohort 1 was from capecitabine monotherapy. Cohort 2 represented capecitabine in combination with other chemotherapeutic agents. Cohort 3 was for capecitabine in combination with other chemotherapeutic and targeted agents. Cohort 4 was from the capecitabine in combination with other chemotherapeutic agents as well as immunosuppressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,681 AE reports associated with capecitabine were included (632 cases in Cohort 1, 816 cases in Cohort 2, 189 cases in Cohort 3, and 44 cases in Cohort 4). The outcomes of AEs were predominantly other medical events, hospitalization or prolonged hospitalization, and death. Gastrointestinal disorders, general disorders and administration site conditions were the most frequently affected SOCs. The most frequent AEs in Cohort 1 were death (n = 83), diarrhea (n = 75), and nausea (n = 73), whereas the strongest signal was palmar-plantar erythrodysaesthesia syndrome (n = 43, ROR = 4.62). In Cohort 2, diarrhoea (n = 160), vomiting (n = 146), and nausea (n = 143) were the most frequently reported AEs, whereas palmar-plantar erythrodysaesthesia syndrome showed the strongest signal (n = 95, ROR = 6.69). In Cohort 3, leukoencephalopathy exhibited the strongest signal (n = 7, ROR = 21.79). In Cohort 4, sleep disorder (n = 5, ROR = 95.98, 95% CI: 33.54\u2013274.69), dry mouth (n = 5, ROR = 35.98, 95% CI: 13.89\u201393.18), and inappropriate schedule of product administration (n = 5, ROR = 28.78, 95% CI: 11.25\u201373.59) appeared as novel, robust signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Capecitabine showed distinct AE profiles in different GC regimens, with both prevalent and rare signals. Tailored safety monitoring is needed based on combination regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1861329","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:55Z","timestamp":1789104715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events of capecitabine in gastric cancer patients: a real\u2010world pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Ru","family":"Sang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbing","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/or.2023.8612","article-title":"5-Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review)","volume":"50","author":"Alzahrani","year":"2023","journal-title":"Oncol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/biology9090265","article-title":"5-Fluorouracil conversion pathway mutations in gastric cancer","volume":"9","author":"Biagioni","year":"2020","journal-title":"Biology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2408269","DOI":"10.1155\/2016\/2408269","article-title":"Capecitabine induced multifocal leukoencephalopathy: do we have always to switch off the chemotherapy?","volume":"2016","author":"Bougea","year":"2016","journal-title":"Case Rep. Oncol. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41416-024-02754-z","article-title":"DPYD genetic polymorphisms in Non-European patients with severe fluoropyrimidine-related toxicity: a systematic review","volume":"131","author":"Chan","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3969\/j.issn.2095-1264.2022.05.12","article-title":"Research on signal mining of fluorouracil and capecitabine adverse events based on FAERS database","volume":"13","author":"Chen","year":"2022","journal-title":"Zhongliu Yaoxue"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1012093","DOI":"10.3389\/fonc.2022.1012093","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2022","journal-title":"Front. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"109066","DOI":"10.1016\/j.abb.2021.109066","article-title":"Mammalian dihydropyrimidine dehydrogenase","volume":"714","author":"Forouzesh","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2169\/internalmedicine.8636-21","article-title":"Severe gastrointestinal disorder due to capecitabine associated with dihydropyrimidine dehydrogenase deficiency: a case report and literature review","volume":"61","author":"Hagiwara","year":"2022","journal-title":"Intern. Med. (Tokyo, Japan)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"930470","DOI":"10.3389\/fphar.2022.930470","article-title":"Importance of rare DPYD genetic polymorphisms for 5-Fluorouracil therapy in the Japanese population","volume":"13","author":"Hishinuma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.trecan.2020.02.009","article-title":"On a new proposed mechanism of 5-Fluorouracil-Mediated cytotoxicity","volume":"6","author":"Hussain","year":"2020","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s10120-023-01423-z","article-title":"Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study","volume":"26","author":"Kawabata","year":"2023","journal-title":"Gastric Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1186\/s12889-024-19104-6","article-title":"Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035","volume":"24","author":"Lin","year":"2024","journal-title":"BMC Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"20420986241303428","DOI":"10.1177\/20420986241303428","article-title":"Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Liu","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10020-022-00516-2","article-title":"MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy","volume":"28","author":"Matuszyk","year":"2022","journal-title":"Mol. Med. (Camb. Mass)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy Versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.abd.2022.05.004","article-title":"Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - a literature review","volume":"98","author":"Nascimento","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-024-01788-2","article-title":"XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial","volume":"9","author":"Pan","year":"","journal-title":"Signal Transduct. Target. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1431579","DOI":"10.3389\/fphar.2024.1431579","article-title":"Neurological adverse events associated with oxaliplatin: a pharmacovigilance analysis based on FDA adverse event reporting system","volume":"15","author":"Pan","year":"","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/ene.14857","article-title":"Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine","volume":"28","author":"Perrain","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1053\/j.gastro.2018.11.076","article-title":"Capecitabine-induced enteritis leading to small bowel obstruction","volume":"156","author":"Pow-Anpongkul","year":"2019","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100151","DOI":"10.1016\/j.cmpbup.2024.100151","article-title":"S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: a systematic review and meta-analysis","volume":"5","author":"Qadar","year":"2024","journal-title":"Comput. Methods Programs Biomed. Update"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","article-title":"Topical diclofenac for prevention of Capecitabine-Associated hand-foot syndrome: a double-blind randomized controlled trial","volume":"42","author":"Santhosh","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"20420986251405091","DOI":"10.1177\/20420986251405091","article-title":"Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration adverse event reporting system and Canada vigilance adverse reaction online database","volume":"16","author":"Sha","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14740338.2021.1887850","article-title":"Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?","volume":"20","author":"Tomao","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial","volume":"325","author":"Wang","year":"2021","journal-title":"Jama"},{"key":"B28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"","journal-title":"Cancer Comm. Lond. Engl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1412938","DOI":"10.3389\/fphar.2024.1412938","article-title":"Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS","volume":"15","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1423891","DOI":"10.3389\/fphar.2024.1423891","article-title":"Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"15","author":"Xie","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41571-023-00834-2","article-title":"Personalizing adjuvant therapy for patients with colorectal cancer","volume":"21","author":"Yang","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e102484","DOI":"10.1371\/journal.pone.0102484","article-title":"Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis","volume":"9","author":"Zuo","year":"2014","journal-title":"PloS One"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:57Z","timestamp":1789104717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":32,"alternative-id":["10.3389\/fphar.2026.1861329"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1861329","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1861329"}}